These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28641200)

  • 1. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.
    Spänkuch I; Gassenmaier M; Tampouri I; Noor S; Forschner A; Garbe C; Amaral T
    Eur J Cancer; 2017 Aug; 81():203-205. PubMed ID: 28641200
    [No Abstract]   [Full Text] [Related]  

  • 2. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
    Gupta A; Shah U; Khine H; Vandergriff T; Froehlich T
    Melanoma Res; 2017 Apr; 27(2):171-173. PubMed ID: 28099367
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
    Sato M; Uhara H; Koga H; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
    [No Abstract]   [Full Text] [Related]  

  • 5. Discontinuation of melanoma combination immunotherapy.
    Baker H
    Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
    [No Abstract]   [Full Text] [Related]  

  • 6. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
    Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune checkpoint inhibitors-related orchitis.
    Brunet-Possenti F; Opsomer MA; Gomez L; Ouzaid I; Descamps V
    Ann Oncol; 2017 Apr; 28(4):906-907. PubMed ID: 28039179
    [No Abstract]   [Full Text] [Related]  

  • 8. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
    Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
    [No Abstract]   [Full Text] [Related]  

  • 9. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.
    Mirza S; Hill E; Ludlow SP; Nanjappa S
    Melanoma Res; 2017 Jun; 27(3):271-273. PubMed ID: 28146044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
    Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
    Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
    J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
    [No Abstract]   [Full Text] [Related]  

  • 12. [Histoseminar on inflammatory bowel diseases (IBD): Case n
    Fléjou JF
    Ann Pathol; 2017 Aug; 37(4):298-301. PubMed ID: 28734677
    [No Abstract]   [Full Text] [Related]  

  • 13. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
    Eggermont AMM; Dummer R
    Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
    Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
    J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy in colorectal cancer with mismatch repair deficiency.
    Overman MJ
    Clin Adv Hematol Oncol; 2019 May; 17(5):265-267. PubMed ID: 31188802
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
    Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
    J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
    Numata S; Iwata Y; Okumura R; Arima M; Kobayashi T; Watanabe S; Suzuki K; Horiguchi M; Sugiura K
    J Dermatol; 2018 Jan; 45(1):113-114. PubMed ID: 28225147
    [No Abstract]   [Full Text] [Related]  

  • 18. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
    Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
    Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
    [No Abstract]   [Full Text] [Related]  

  • 19. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma.
    Koksal AS; Toka B; Eminler AT; Hacibekiroglu I; Uslan MI; Parlak E
    Ann Oncol; 2017 Dec; 28(12):3103-3104. PubMed ID: 28945827
    [No Abstract]   [Full Text] [Related]  

  • 20. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.